[Genetic basis for skeletal disease. CNP therapy for achondroplasia].
By using transgenic and knockout mice, we have elucidated that C-type natriuretic peptide (CNP) is a potent stimulator of endochondral bone growth. Furthermore, loss-of-function mutations in the gene coding for guanylyl cyclase-B (GC-B) , the specific receptor for CNP, have been proved to cause impaired skeletal growth in humans. Following these results, we have started to translate the stimulatory effect of CNP on endochondral bone growth into the therapy for patients with achondroplasia, and have shown that targeted overexpression of CNP in cartilage or systemic administration of CNP reverses the impaired skeletal growth of mice model of achondroplasia.
Yasoda
Akihiro
A
Medicine and Clinical Science, Kyoto University Graduate School of Medicine.
Nakao
Kazuwa
K
D000130:Achondroplasia / Q000188:drug therapy* / Q000503:physiopathology; D000818:Animals; D002356:Cartilage / Q000254:growth & development; D004195:Disease Models, Animal; D006801:Humans; D051379:Mice; D018345:Mice, Knockout; D008822:Mice, Transgenic; D009154:Mutation; D020098:Natriuretic Peptide, C-Type / Q000627:therapeutic use*; D017461:Receptors, Atrial Natriuretic Factor / Q000235:genetics; D000099242:Atrial Natriuretic Factor Receptor B
D020098:Natriuretic Peptide, C-Type; D017461:Receptors, Atrial Natriuretic Factor; D000099242:Atrial Natriuretic Factor Receptor B